Clinical-stage biotech company Bloom Science Inc announced on Tuesday that the first patient has been dosed in its Phase 1b clinical trial evaluating BL-001 in adults with obesity.
The randomised, double-blind, placebo-controlled trial is designed to assess the safety, tolerability, and weight loss impacts of daily oral BL-001 administered for 12 weeks in adults with obesity.
Up to 48 participants will be enrolled across two clinical sites in Australia.
BL-001, an investigational oral Live Biotherapeutic Product (LBP), is designed to replicate key metabolic effects of the ketogenic diet without requiring dietary restriction.
AlzeCure's ACD440 granted EU orphan drug status for erythromelalgia
Armata Pharmaceuticals' AP-SA02 receives QIDP designation from US FDA
Astellas Pharma signs global strategic collaboration with Vir Biotechnology
Illumina sets out 18-Month NovaSeq X roadmap to boost sequencing performance and scale
Gossamer Bio reports topline Phase 3 PROSERA results for seralutinib in PAH
Novo Nordisk's CagriSema achieves 23% weight loss but misses primary endpoint in REDEFINE 4 trial
NICE recommends epcoritamab for relapsed or refractory follicular lymphoma
AbbVie's VENCLEXTA (venetoclax) and acalabrutinib combination receives US FDA approval to treat CLL
FDA approves Genentech oral Venclexta plus AstraZeneca's Calquence combination for first-line CLL
Moleculin exercises warrants for USD8.3m gross proceeds
Eupraxia Pharmaceuticals prices USD55m public offering
Lario Therapeutics awarded USD2.4m in grants for neuronal calcium channel research
EMA validates Enhertu application for post-neoadjuvant HER2-positive early breast cancer
Merck reports positive Phase 3 data for Enflonsia in high-risk children across two RSV seasons